This study is for individuals who have Cushings disease and want to join voluntarily in this study to find out if a study drug called osilodrostat (LCI699) is safe and has beneficial effects in people who have Cushings disease. Cushings disease is a rare but debilitating disease. Cushings disease is caused by a benign tumor of the pituitary gland. The tumor…
The purpose of this study is to determine if measuring blood levels of proteins called POMC, AgRP, and chromogrannin A (CGA) can be used to diagnose and track tumor growth and recurrence in patients that have ACTH-dependent Cushing's syndrome, non-secreting pituitary tumors, and other neuroendocrine tumors. We invite you to participate if you have: a…
The purpose of this study is to collect blood samples from women who are pregnant with a fetus that has been confirmed by prenatal microarray testing to have a chromosomal abnormality, such as a microdeletion (missing chromosomes) or microduplication (extra chromosomes). The sponsor of this study, Sequenom Laboratories, will use these samples to develop and…
The purpose of this study is to evaluate the safety and effectiveness of ATryn, for the treatment of early onset preeclampsia (high blood pressure during pregnancy). ATryn is is currently approved by the Food and Drug Administration (FDA) and is used to prevent blood clots from forming in patients who are having surgery or giving birth to a child. Eligible…
The purpose of this study is to confirm the effectiveness and safety of LCI699 in treating patients with Cushing's disease. Patients will be treated with the invesitigational drug LCI699 at doses up to 60 mg a day, and possibly for a short period of time with placebo. A placebo is a dummy drug ("pill") with no active medicine inside.